A Novel Chemoimmunomodulating Property of Docetaxel: Suppression of Myeloid-Derived Suppressor Cells in Tumor Bearers
Open accessAbstract
Purpose: Myeloid-derived suppressor cells (MDSC) accumulate in tumor-bearing hosts and are associated with immune suppression. To date, there have only been few studies that evaluate the direct effect of chemotherapeutic agents on MDSCs. Agents that inhibit MDSCs may be useful in the treatment of patients with various cancers. Experimental Design: We investigated the in vivo effects of docetaxel on immune function in 4T1-Neu mammary tumor-bearing mice to examine if a favorable immunomodulatory effect accompanies tumor suppression. Primary focus was on the differentiation status of MDSCs and their ability to modulate T-cell responses. Results: Docetaxel administration significantly inhibited tumor growth in 4T1-Neu tumor-bearing mice and considerably decreased MDSC proportion in the spleen. The treatment also selectively increased CTL responses. Docetaxel-pretreated MDSCs cocultured with OT-II splenocytes in the presence of OVA323-339 showed OT-II–specific CD4 activation and expansion in vitro. In characterizing the phenotype of MDSCs for M1 (CCR7) and M2 [mannose receptor (CD206)] markers, MDSCs from untreated tumor bearers were primarily MR+ with few CCR7+ cells. Docetaxel treatment polarized MDSCs toward an M1-like phenotype, resulting in 40% of MDSCs expressing CCR7 in vivo and in vitro, and macrophage differentiation markers such as MHC class II, CD11c, and CD86 were upregulated. Interestingly, docetaxel induced cell death selectively in MR+ MDSCs while sparing the M1-like phenotype. Finally, inhibition of signal transducer and activator of transcription 3 may in part be responsible for the observed results. Conclusions: These findings suggest potential clinical benefit for the addition of docetaxel to current immunotherapeutic protocols. Clin Cancer Res; 16(18); 4583–94. ©2010 AACR.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
5-fluorouracil, doxorubicin, gemcitabine, and docetaxel reduced circulating myeloid-derived suppressor cells (MDSCs) in mouse models.
“although 5-fluorouracil, doxorubicin, gemcitabine, and docetaxel reduced circulating myeloid-derived suppressor cells (MDSCs) in mouse models [42–45]”
From Combination strategies with PD-1/PD-L1 blockade: current advances and future directions (2022) · cites this paper as [45]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Myeloid-derived-suppressor cells as regulators of the immune system
Gabrilovich, D. I., & Nagaraj, S. (2009) · Nature Reviews Immunology · doi:10.1038/nri2506 · Cited by 6,753 · see citing works
The chemokine system in diverse forms of macrophage activation and polarization
MANTOVANI, A., SICA, A., SOZZANI, S., ALLAVENA, P., VECCHI, A., & LOCATI, M. (2004) · Trends in Immunology · doi:10.1016/j.it.2004.09.015 · Cited by 6,534 · see citing works
MANTOVANI, A., SOZZANI, S., LOCATI, M., ALLAVENA, P., & SICA, A. (2002) · Trends in Immunology · doi:10.1016/s1471-4906(02)02302-5 · Cited by 5,528 · see citing works
M-1/M-2 Macrophages and the Th1/Th2 Paradigm
Mills, C. D., Kincaid, K., Alt, J. M., Heilman, M. J., & Hill, A. M. (2000) · The Journal of Immunology · doi:10.4049/jimmunol.164.12.6166 · Cited by 3,287 · see citing works
Taxol stabilizes microtubules in mouse fibroblast cells.
Schiff, P. B., & Horwitz, S. B. (1980) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.77.3.1561 · Cited by 1,971 · see citing works
Subsets of Myeloid-Derived Suppressor Cells in Tumor-Bearing Mice
Youn, J., Nagaraj, S., Collazo, M. M., & Gabrilovich, D. I. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.181.8.5791 · Cited by 1,645 · see citing works
Almand, B., Clark, J. I., Nikitina, E., van Beynen, J., English, N. R., Knight, S. C., Carbone, D. P., & Gabrilovich, D. I. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.166.1.678 · Cited by 1,340 · see citing works
Altered macrophage differentiation and immune dysfunction in tumor development
Sica, A., & Bronte, V. (2007) · Journal of Clinical Investigation · doi:10.1172/jci31422 · Cited by 1,239 · see citing works
Diaz-Montero, C. M., Salem, M. L., Nishimura, M. I., Garrett-Mayer, E. S., Cole, D. J., & Montero, A. J. (2008) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-008-0523-4 · Cited by 1,217 · see citing works
Suzuki, E., Kapoor, V., Jassar, A. S., Kaiser, L. R., & Albelda, S. M. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-0883 · Cited by 1,054 · see citing works
Inhibiting Stat3 signaling in the hematopoietic system elicits multicomponent antitumor immunity
Kortylewski, M., Kujawski, M., Wang, T., Sheng, W., Zhang, S., Pilon‐Thomas, S., Niu, G., Kay, H. D., Mulé, J. J., Kerr, W. G., et al. (2005) · Nature Medicine · doi:10.1038/nm1325 · Cited by 1,026 · see citing works
Chalmin, F., Ladoire, S., Mignot, G., Vincent, J., Bruchard, M., Rémy-Martin, J.-P., Boireau, W., Rouleau, A., Simon, B., Lanneau, D., et al. (2010) · Journal of Clinical Investigation · doi:10.1172/jci40483 · Cited by 998 · see citing works
Kusmartsev, S. A., Nefedova, Y., Yoder, D., & Gabrilovich, D. I. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.172.2.989 · Cited by 851 · see citing works
Tumors induce a subset of inflammatory monocytes with immunosuppressive activity on CD8+ T cells
Gallina, G., Dolcetti, L., Serafini, P., Santo, C. D., Marigo, I., Colombo, M. P., Basso, G., Brombacher, F., Borrello, I., Zanovello, P., et al. (2006) · Journal of Clinical Investigation · doi:10.1172/jci28828 · Cited by 792 · see citing works
Serafini, P., Meckel, K. F., Kelso, M., Noonan, K. A., Califano, J. A., Koch, W. M., Dolcetti, L., Bronte, V., & Borrello, I. (2006) · The Journal of Experimental Medicine · doi:10.1084/jem.20061104 · Cited by 767 · see citing works
Proinflammatory S100 Proteins Regulate the Accumulation of Myeloid-Derived Suppressor Cells
Sinha, P., Okoro, C., Foell, D., Freeze, H. H., Ostrand‐Rosenberg, S., & Srikrishna, G. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.181.7.4666 · Cited by 722 · see citing works
Myeloid Suppressor Lines Inhibit T Cell Responses by an NO-Dependent Mechanism
Mazzoni, A., Bronte, V., Visintin, A., Spitzer, J. H., Apolloni, E., Serafini, P., Zanovello, P., & Segal, D. M. (2002) · The Journal of Immunology · doi:10.4049/jimmunol.168.2.689 · Cited by 692 · see citing works
Bunt, S. K., Yang, L., Sinha, P., Clements, V. K., Leips, J., & Ostrand‐Rosenberg, S. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-2354 · Cited by 630 · see citing works
Ozao-Choy, J., Ma, G., Kao, J., Wang, G. X., Meseck, M., Sung, M., Schwartz, M., Divino, C. M., Pan, P.-Y., & Chen, S.-H. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-4709 · Cited by 538 · see citing works
Terabe, M., Matsui, S., Park, J.-M., Mamura, M., Noben-Trauth, N., Donaldson, D. D., Chen, W., Wahl, S. M., Ledbetter, S. R., Pratt, B. M., et al. (2003) · The Journal of Experimental Medicine · doi:10.1084/jem.20022227 · Cited by 533 · see citing works
Hyperactivation of STAT3 is involved in abnormal differentiation of dendritic cells in cancer
Nefedova, Y., Huang, M., Kusmartsev, S., Bhattacharya, R., Cheng, P., Salup, R., Jove, R., & Gabrilovich, D. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.172.1.464 · Cited by 464 · see citing works
Kusmartsev, S. A., Cheng, F., Yu, B., Nefedova, Y., Sotomayor, E. M., Lush, R. M., & Gabrilovich, D. I. (2003) · PubMed · Cited by 460 · see citing works
New vistas on macrophage differentiation and activation
Mantovani, A., Sica, A., & Locati, M. (2006) · European Journal of Immunology · doi:10.1002/eji.200636910 · Cited by 431 · see citing works
Kusmartsev, S. A., Yu, L., & Chen, S. (2000) · The Journal of Immunology · doi:10.4049/jimmunol.165.2.779 · Cited by 352 · see citing works
Umemura, N., Saio, M., Suwa, T., Kitoh, Y., Bai, J., Nonaka, K., Ouyang, G., Okada, M., Balázs, M., Ádány, R., et al. (2008) · Journal of Leukocyte Biology · doi:10.1189/jlb.0907611 · Cited by 347 · see citing works
Role Of Immature Myeloid Cells in Mechanisms of Immune Evasion In Cancer
Kusmartsev, S. A., & Gabrilovich, D. I. (2005) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-005-0048-z · Cited by 346 · see citing works
Mantovani, A., Sica, A., Allavena, P., Garlanda, C., & Locati, M. (2009) · Human Immunology · doi:10.1016/j.humimm.2009.02.008 · Cited by 345 · see citing works
Immune changes in patients with advanced breast cancer undergoing chemotherapy with taxanes
Tsavaris, N., Kosmas, C., Vadiaka, M., Kanelopoulos, P., & Boulamatsis, D. (2002) · British Journal of Cancer · doi:10.1038/sj.bjc.6600347 · Cited by 343 · see citing works
Derangement of immune responses by myeloid suppressor cells
Serafini, P., Santo, C. D., Marigo, I., Cingarlini, S., Dolcetti, L., Gallina, G., Zanovello, P., & Bronte, V. (2003) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-003-0443-2 · Cited by 335 · see citing works
Nefedova, Y., Nagaraj, S., Rosenbauer, A., Muro‐Cacho, C., Sebti, S. M., & Gabrilovich, D. I. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-0529 · Cited by 318 · see citing works
Garnett‐Benson, C., Schlom, J., & Hodge, J. W. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-4025 · Cited by 232 · see citing works
Young, M. R., Newby, M., & Wepsic, H. T. (1987) · PubMed · Cited by 231 · see citing works
Therapeutic targeting of myeloid-derived suppressor cells
Ugel, S., Delpozzo, F., Desantis, G., Papalini, F., Simonato, F., Sonda, N., Zilio, S., & Bronte, V. (2009) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2009.06.014 · Cited by 206 · see citing works
Wei, S., Gamero, A. M., Liu, J. H., Daulton, A. A., Valkov, N. I., Trapani, J. A., Larner, A. C., Weber, M. J., & Djeu, J. Y. (1998) · The Journal of Experimental Medicine · doi:10.1084/jem.187.11.1753 · Cited by 149 · see citing works
Self-citationVicari, A. P., Luu, R., Zhang, N., Patel, S., Makinen, S. R., Hanson, D. C., Weeratna, R. D., & Krieg, A. Μ. (2008) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-008-0586-2 · Cited by 127 · see citing works
Novel role of Stat1 in the development of docetaxel resistance in prostate tumor cells
Patterson, S. G., Wei, S., Chen, X., Sallman, D. A., Gilvary, D. L., Zhong, B., Pow‐Sang, J. M., Yeatman, T., & Djeu, J. Y. (2006) · Oncogene · doi:10.1038/sj.onc.1209632 · Cited by 117 · see citing works
Self-citationQuantitative Validation and Comparison of Multiplex Cytokine Kits
Richens, J. L., Urbanowicz, R. A., Metcalf, R., Corne, J. M., O’Shea, P., & Fairclough, L. C. (2010) · SLAS DISCOVERY · doi:10.1177/1087057110362099 · Cited by 106 · see citing works
Burkhart, C. A., Berman, J. W., Swindell, C. S., & Horwitz, S. B. (1994) · PubMed · Cited by 91 · see citing works
From phagocyte diversity and activation to probiotics: Back to Metchnikoff
Mantovani, A. (2008) · European Journal of Immunology · doi:10.1002/eji.200838918 · Cited by 78 · see citing works
Induction of Clusterin by AKT—Role in Cytoprotection against Docetaxel in Prostate Tumor Cells
Zhong, B., Sallman, D. A., Gilvary, D. L., Pernazza, D., Sahakian, E., Fritz, D., Cheng, J. Q., Trougakos, I. P., Sheng, W., & Djeu, J. Y. (2010) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-09-0880 · Cited by 56 · see citing works
Self-citationAn In Vivo Evaluation of Docetaxel Delivered Intratumorally in Head and Neck Squamous Cell Carcinoma
Yoo, G. H., Subramanian, G., Boinpally, R., Iskander, A. J., Shehadeh, N. J., Oliver, J. W., Ezzat, W. H., Piechocki, M. P., Ensley, J. F., Lin, H.-S., et al. (2005) · Archives of Otolaryngology - Head and Neck Surgery · doi:10.1001/archotol.131.5.418 · Cited by 14 · see citing works
Flagged first, then by citations
1 of the 42 references couldn’t be matched to a known paper.
Cited by
Sorted by citations
Coordinated regulation of myeloid cells by tumours
Gabrilovich, D. I., Ostrand-Rosenberg, S., & Bronte, V. (2012) · Nature Reviews Immunology · doi:10.1038/nri3175 · Cited by 3,544 · see citing works
Inflammation and tumor progression: signaling pathways and targeted intervention
Zhao, H., Wu, L., Yan, G., Chen, Y., Zhou, M., Wu, Y., & Li, Y. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00658-5 · Cited by 2,987 · see citing works
Combination strategies with PD-1/PD-L1 blockade: current advances and future directions
Yi, M., Zheng, X., Niu, M., Zhu, S., Ge, H., & Wu, K. (2022) · Molecular Cancer · doi:10.1186/s12943-021-01489-2 · Cited by 1,445 · see citing works
Immunostimulation with chemotherapy in the era of immune checkpoint inhibitors
Galluzzi, L., Humeau, J., Buqué, A., Zitvogel, L., & Kroemer, G. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-0413-z · Cited by 1,349 · see citing works
Cellular Senescence: Aging, Cancer, and Injury
Calcinotto, A., Kohli, J., Zagato, E., Pellegrini, L., Demaria, M., & Alimonti, A. (2019) · Physiological Reviews · doi:10.1152/physrev.00020.2018 · Cited by 1,270 · see citing works
History of myeloid-derived suppressor cells
Talmadge, J. E., & Gabrilovich, D. I. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3581 · Cited by 1,148 · see citing works
Macrophage Regulation of Tumor Responses to Anticancer Therapies
De Palma, M., & Lewis, C. E. (2013) · Cancer Cell · doi:10.1016/j.ccr.2013.02.013 · Cited by 1,079 · see citing works
Bracci, L., Schiavoni, G., Sistigu, A., & Belardelli, F. (2013) · Cell Death and Differentiation · doi:10.1038/cdd.2013.67 · Cited by 931 · see citing works
Zitvogel, L., Galluzzi, L., Smyth, M. J., & Kroemer, G. (2013) · Immunity · doi:10.1016/j.immuni.2013.06.014 · Cited by 901 · see citing works
Progress in tumor-associated macrophage (TAM)-targeted therapeutics
Ngambenjawong, C., Gustafson, H. H., & Pun, S. H. (2017) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2017.04.010 · Cited by 854 · see citing works
The Interplay of Immunotherapy and Chemotherapy: Harnessing Potential Synergies
Emens, L. A., & Middleton, G. (2015) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-15-0064 · Cited by 830 · see citing works
Cell death-based treatment of lung adenocarcinoma
Denisenko, T. V., Budkevich, I. N., & Zhivotovsky, B. (2018) · Cell Death & Disease · doi:10.1038/s41419-017-0063-y · Cited by 768 · see citing works
Vaccines for established cancer: overcoming the challenges posed by immune evasion
van der Burg, S. H., Arens, R., OSSENDORP, F. A., van Hall, T., & Melief, C. J. M. (2016) · Nature reviews. Cancer · doi:10.1038/nrc.2016.16 · Cited by 709 · see citing works
Macrophages and cancer: from mechanisms to therapeutic implications
Ostuni, R., Kratochvill, F., Murray, P. J., & Natoli, G. (2015) · Trends in Immunology · doi:10.1016/j.it.2015.02.004 · Cited by 685 · see citing works
The secret ally: immunostimulation by anticancer drugs
Galluzzi, L., Senovilla, L., Zitvogel, L., & Kroemer, G. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3626 · Cited by 670 · see citing works
Neutralization of Tumor Acidity Improves Antitumor Responses to Immunotherapy
Pilon-Thomas, S., Kodumudi, K. N., El-Kenawi, A. E., Russell, S., Weber, A. M., Luddy, K., Damaghi, M., Wojtkowiak, J. W., Mulé, J. J., Ibrahim-Hashim, A., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-1743 · Cited by 593 · see citing works
Self-citationHeinhuis, K. M., Ros, W., Kok, M., Steeghs, N., Beijnen, J. H., & Schellens, J. H. M. (2019) · Annals of Oncology · doi:10.1093/annonc/mdy551 · Cited by 556 · see citing works
Perivascular M2 Macrophages Stimulate Tumor Relapse after Chemotherapy
Hughes, R., Qian, B., Rowan, C., Muthana, M., Keklikoglou, I., Olson, O. C., Tazzyman, S. J., Danson, S. J., Addison, C., Clemons, M. J., et al. (2015) · Cancer Research · doi:10.1158/0008-5472.can-14-3587 · Cited by 516 · see citing works
Myeloid-Derived Suppressor Cells as a Therapeutic Target for Cancer
Law, A. M. K., Valdes-Mora, F., & Gallego-Ortega, D. (2020) · Cells · doi:10.3390/cells9030561 · Cited by 455 · see citing works
Recent Advances in Hyperthermia Therapy‐Based Synergistic Immunotherapy
Chang, M., Hou, Z., Wang, M., Li, C., & Lin, J. (2020) · Advanced Materials · doi:10.1002/adma.202004788 · Cited by 452 · see citing works
Targeting Myeloid-Derived Suppressor Cells to Bypass Tumor-Induced Immunosuppression
Fleming, V., Hu, X., Weber, R., Nagibin, V. S., Groth, C., Altevogt, P., Utikal, J. S., & Umansky, V. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00398 · Cited by 444 · see citing works
Alizadeh, D., Trad, M., Hanke, N. T., Larmonier, C. B., Janikashvili, N., Bonnotte, B., Katsanis, E., & Larmonier, N. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-1545 · Cited by 416 · see citing works
Towards targeting the breast cancer immune microenvironment
Harris, M. A., Savas, P. S., Virassamy, B., O’Malley, M. M. R., Kay, J., Mueller, S. N., Mackay, L. K., Salgado, R., & Loi, S. (2024) · Nature reviews. Cancer · doi:10.1038/s41568-024-00714-6 · Cited by 398 · see citing works
Recent advances in triple negative breast cancer: the immunotherapy era
Marra, A., Viale, G., & Curigliano, G. (2019) · BMC Medicine · doi:10.1186/s12916-019-1326-5 · Cited by 352 · see citing works
Cicco, P. D., Ercolano, G., & Ianaro, A. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01680 · Cited by 338 · see citing works
Chen, L., Zhou, L., Wang, C., Han, Y., Lu, Y., Liu, J., Hu, X., Yao, T., Lin, Y., Liang, S., et al. (2019) · Advanced Materials · doi:10.1002/adma.201904997 · Cited by 337 · see citing works
A Review on Nano-Based Drug Delivery System for Cancer Chemoimmunotherapy
Mu, W., Chu, Q., Liu, Y., & Zhang, N. (2020) · Nano-Micro Letters · doi:10.1007/s40820-020-00482-6 · Cited by 336 · see citing works
Interaction of tumor-associated macrophages and cancer chemotherapy
Larionova, I., Cherdyntseva, N., Liu, T., Patysheva, M., Rakina, M., & Kzhyshkowska, J. (2019) · OncoImmunology · doi:10.1080/2162402x.2019.1596004 · Cited by 322 · see citing works
Therapeutic Cancer Vaccines: Current Status and Moving Forward
Schlom, J. (2012) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djs033 · Cited by 282 · see citing works
Li, L., Wang, L., Li, J., Fan, Z., Li, Y., Zhang, Z., Zhang, C., Yue, D., Qin, G., Zhang, T., et al. (2018) · Cancer Research · doi:10.1158/0008-5472.can-17-2460 · Cited by 266 · see citing works
He, S., Zheng, L., & Qi, C. (2025) · Molecular Cancer · doi:10.1186/s12943-024-02208-3 · Cited by 249 · see citing works
Immunotherapy of Prostate Cancer: Facts and Hopes
Bilušić, M., Madan, R. A., & Gulley, J. L. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-0019 · Cited by 253 · see citing works
Turnquist, H. R., Zhao, Z., Rosborough, B. R., Liu, Q., Castellaneta, A., Isse, K., Wang, Z., Lang, M. A., Stolz, D. B., Zheng, X. X., et al. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1100519 · Cited by 244 · see citing works
Chemoimmunotherapy: Reengineering Tumor Immunity
Chen, G., & Emens, L. A. (2013) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-012-1388-0 · Cited by 242 · see citing works
Nivolumab in NSCLC: latest evidence and clinical potential
Sundar, R., Cho, B. C., Brahmer, J. R., & Soo, R. A. (2015) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758834014567470 · Cited by 234 · see citing works
Current Status and Future Directions
Ito, F., & Chang, A. E. (2013) · Cited by 223 · see citing works
The multifaceted immune regulation of bladder cancer
Schneider, A. K., Chevalier, M. F., & Derré, L. (2019) · Nature Reviews Urology · doi:10.1038/s41585-019-0226-y · Cited by 222 · see citing works
Vaccine Strategies to Improve Anti-cancer Cellular Immune Responses
Vermaelen, K. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00008 · Cited by 221 · see citing works
PD-1/PD-L1 Targeting in Breast Cancer: The First Clinical Evidences are Emerging—A Literature Review
Planes-Laine, G., Rochigneux, P., Bertucci, F., Chrétien, A.-S., Viens, P., Sabatier, R., & Gonçalvès, A. (2019) · Cancers · doi:10.3390/cancers11071033 · Cited by 225 · see citing works
Tumor-associated myeloid cells: diversity and therapeutic targeting
Mantovani, A., Marchesi, F., Jaillon, S., Garlanda, C., & Allavena, P. (2021) · Cellular and Molecular Immunology · doi:10.1038/s41423-020-00613-4 · Cited by 218 · see citing works
Immunogenic Cell Death Inducing Metal Complexes for Cancer Therapy
Zhang, L., Montesdeoca, N., Karges, J., & Xiao, H. (2023) · Angewandte Chemie International Edition · doi:10.1002/anie.202300662 · Cited by 217 · see citing works
Bruno, A., Mortara, L., Baci, D., Noonan, D. M., & Albini, A. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00771 · Cited by 216 · see citing works
The Tumor Immune Contexture of Prostate Cancer
Vitkin, N., Nersesian, S., Siemens, D. R., & Koti, M. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00603 · Cited by 217 · see citing works
Cancer‐promoting tumor‐associated macrophages: New vistas and open questions
Mantovani, A., Germano, G., Marchesi, F., Locatelli, M., & Biswas, S. K. (2011) · European Journal of Immunology · doi:10.1002/eji.201141894 · Cited by 205 · see citing works
Leonetti, A., Wever, B. M. M., Mazzaschi, G., Assaraf, Y. G., Rolfo, C. D., Quaini, F., Tiseo, M., & Giovannetti, E. (2019) · Drug Resistance Updates · doi:10.1016/j.drup.2019.100644 · Cited by 201 · see citing works
Tumor-Associated Macrophages as Target for Antitumor Therapy
Sawa-Wejksza, K., & Kandefer‐Szerszeń, M. (2017) · Archivum Immunologiae et Therapiae Experimentalis · doi:10.1007/s00005-017-0480-8 · Cited by 207 · see citing works
Recent Progress in GM-CSF-Based Cancer Immunotherapy
Yan, W.-L., Shen, K., Tien, C.-Y., Chen, Y., & Liu, S. (2017) · Immunotherapy · doi:10.2217/imt-2016-0141 · Cited by 194 · see citing works
Tumor-Associated Macrophages as Multifaceted Regulators of Breast Tumor Growth
Munir, M. T., Kay, M., Kang, M.-H., Rahman, M. M., Al‐Harrasi, A., Choudhury, M., Moustaïd‐Moussa, N., Hussain, F., & Rahman, S. M. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22126526 · Cited by 196 · see citing works
Hossain, D. M. S., Pal, S. K., Moreira, D., Duttagupta, P. A., Zhang, Q., Won, H., Jones, J. O., D’Apuzzo, M., Forman, S. J., & Kortylewski, M. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-3145 · Cited by 192 · see citing works
Jo, Y., Choi, N., Kim, K., Koo, H., Choi, J. H., & Kim, H. N. (2018) · Theranostics · doi:10.7150/thno.29098 · Cited by 188 · see citing works
Apolipoprotein E induces pathogenic senescent-like myeloid cells in prostate cancer
Bancaro, N., Calì, B., Troiani, M., Elia, A. R., Arzola, R. A., Attanasio, G., Lai, P., Crespo, M., Gürel, B., Pereira, R., et al. (2023) · Cancer Cell · doi:10.1016/j.ccell.2023.02.004 · Cited by 185 · see citing works
Tumor-Associated Macrophage Status in Cancer Treatment
Malfitano, A. M., Pisanti, S., Napolitano, F., Somma, S. D., Martinelli, R., & Portella, G. (2020) · Cancers · doi:10.3390/cancers12071987 · Cited by 183 · see citing works
Li, J. J. X., Tsang, J. Y., & Tse, G. M.-K. (2021) · Cancers · doi:10.3390/cancers13164233 · Cited by 181 · see citing works
Ma, G., Pan, P., Eisenstein, S. G., Divino, C. M., Lowell, C. A., Takai, T., & Chen, S. (2011) · Immunity · doi:10.1016/j.immuni.2011.02.004 · Cited by 175 · see citing works
Biological Effects of Nanoparticles on Macrophage Polarization in the Tumor Microenvironment
Reichel, D., Tripathi, M., & Perez, J. M. (2018) · Nanotheranostics · doi:10.7150/ntno.30052 · Cited by 178 · see citing works
Whole Cell Vaccines—Past Progress and Future Strategies
Keenan, B. P., & Jaffee, E. M. (2012) · Seminars in Oncology · doi:10.1053/j.seminoncol.2012.02.007 · Cited by 167 · see citing works
Tu, S. P., Jin, H., Shi, J. D., Zhu, L. M., Suo, Y., Lü, G., Liu, A., Wang, T. C., & Yang, C. S. (2011) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-11-0247 · Cited by 167 · see citing works
Dominguez, C. L., McCampbell, K. K., David, J. M., & Palena, C. (2017) · JCI Insight · doi:10.1172/jci.insight.94296 · Cited by 167 · see citing works
Kanterman, J., Sade-Feldman, M., Biton, M., Ish‐Shalom, E., Lasry, A., Goldshtein, A., Hubert, A., & Baniyash, M. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-0657 · Cited by 166 · see citing works
Liu, Z., Xie, Y., Xiong, Y., Liu, S., Qiu, C., Zhu, Z., Mao, H., Yu, M., & Wang, X. (2019) · Cancer Letters · doi:10.1016/j.canlet.2019.10.020 · Cited by 165 · see citing works
Michels, T., Shurin, G. V., Naiditch, H., Sevko, A., Umansky, V., & Shurin, M. R. (2012) · Journal of Immunotoxicology · doi:10.3109/1547691x.2011.642418 · Cited by 158 · see citing works
Targeting immune checkpoints in breast cancer: an update of early results
Solinas, C., Gombos, A., Latifyan, S., Piccart, M. J., Kok, M., & Buisseret, L. (2017) · ESMO Open · doi:10.1136/esmoopen-2017-000255 · Cited by 152 · see citing works
Opzoomer, J. W., Sosnowska, D., Anstee, J. E., Spicer, J. F., & Arnold, J. N. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01654 · Cited by 150 · see citing works
Miyauchi, S., Kim, S. S., Pang, J., Gold, K. A., Gutkind, J. S., Califano, J. A., Mell, L. K., Cohen, E. E. W., & Sharabi, A. B. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-0871 · Cited by 151 · see citing works
Rios‐Doria, J., Harper, J. W., Rothstein, R. P., Wetzel, L. K., Chesebrough, J. W., Marrero, A. M., Chen, C., Strout, P., Mulgrew, K. A., McGlinchey, K., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-16-2854 · Cited by 148 · see citing works
Janjigian, Y. Y., Cutsem, E. V., Muro, K., Wainberg, Z. A., Al‐Batran, S., Hyung, W. J., Molena, D., Marcovitz, M., Ruscica, D., Robbins, S. H., et al. (2022) · Future Oncology · doi:10.2217/fon-2022-0093 · Cited by 148 · see citing works
Sasso, M. S., Lollo, G., Pitorre, M., Solito, S., Pinton, L., Valpione, S., Bastiat, G., Mandruzzato, S., Bronte, V., Marigo, I., et al. (2016) · Biomaterials · doi:10.1016/j.biomaterials.2016.04.010 · Cited by 147 · see citing works
Clinical Perspectives on Targeting of Myeloid Derived Suppressor Cells in the Treatment of Cancer
Najjar, Y. G., & Finke, J. H. (2013) · Frontiers in Oncology · doi:10.3389/fonc.2013.00049 · Cited by 145 · see citing works
Chemotherapeutic Targeting of Cancer-Induced Immunosuppressive Cells
Alizadeh, D., & Larmonier, N. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-0301 · Cited by 142 · see citing works
Immune-mediated mechanisms influencing the efficacy of anticancer therapies
Coffelt, S. B., & de Visser, K. E. (2015) · Trends in Immunology · doi:10.1016/j.it.2015.02.006 · Cited by 140 · see citing works
Targeting myeloid-derived suppressor cells to enhance natural killer cell-based immunotherapy
Joshi, S., & Sharabi, A. B. (2022) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2022.108114 · Cited by 140 · see citing works
Butt, A., & Mills, K. H. G. (2013) · Oncogene · doi:10.1038/onc.2013.432 · Cited by 145 · see citing works
Tham, M. J. R., Babak, M. V., & Ang, W. H. (2020) · Angewandte Chemie International Edition · doi:10.1002/anie.202008604 · Cited by 137 · see citing works
Podrazil, M., Horváth, R., Becht, É., Rožková, D., Bílková, P., Sochorová, K., Hromádková, H., Kayserová, J., Vávrová, K., Lašťovička, J., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.4145 · Cited by 136 · see citing works
Tian, J., Ma, J., Ma, K., Guo, H., Baidoo, S. E., Zhang, Y., Yan, J., Lu, L., Xu, H., & Wang, S. (2013) · European Journal of Immunology · doi:10.1002/eji.201242841 · Cited by 134 · see citing works
Targeting tumor associated macrophages: The new challenge for nanomedicine
Andón, F. T., Digifico, E., Maeda, A., Erreni, M., Mantovani, A., Alonso, M. J., & Allavena, P. (2017) · Seminars in Immunology · doi:10.1016/j.smim.2017.09.004 · Cited by 131 · see citing works
Cancer Vaccines: Adjuvant Potency, Importance of Age, Lifestyle, and Treatments
Cuzzubbo, S., Mangsbo, S. M., Nagarajan, D., Habra, K., Pockley, A. G., & McArdle, S. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2020.615240 · Cited by 131 · see citing works
van Steenwijk, P. J. D. V., Ramwadhdoebé, T. H., Goedemans, R., Doorduijn, E. M., van Ham, J. J., Gorter, A., van Hall, T., Kuijjer, M. L., van Poelgeest, M. I. E., van der Burg, S. H., et al. (2013) · International Journal of Cancer · doi:10.1002/ijc.28309 · Cited by 129 · see citing works
Combinatorial prospects of nano-targeted chemoimmunotherapy
Silva, C. G. D., Rueda, F., Löwik, C. W. G. M., OSSENDORP, F. A., & Cruz, L. J. (2016) · Biomaterials · doi:10.1016/j.biomaterials.2016.01.006 · Cited by 128 · see citing works
Optimizing Tumor Microenvironment for Cancer Immunotherapy: β-Glucan-Based Nanoparticles
Zhang, M., Kim, J. A., & Huang, A. Y.-C. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00341 · Cited by 127 · see citing works
Ye, T., Xiong, Y., Yan, Y., Xia, Y., Song, X., Liu, L., Li, D., Wang, N., Zhang, L., Zhu, Y., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0085887 · Cited by 126 · see citing works
Checkpoint inhibitor therapy for metastatic triple-negative breast cancer
Heeke, A. L., & Tan, A. R. (2021) · Cancer and Metastasis Reviews · doi:10.1007/s10555-021-09972-4 · Cited by 131 · see citing works
Drug delivery to macrophages: Challenges and opportunities
Pei, Y., & Yeo, Y. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.12.014 · Cited by 125 · see citing works
Tumor-associated macrophages and anti-tumor therapies: complex links
Belgiovine, C., D’Incalci, M., Allavena, P., & Frapolli, R. (2016) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-016-2166-5 · Cited by 126 · see citing works
Ma, Z., Zhang, W., Dong, B., Xin, Z., Ji, Y., Su, R., Shen, K., Pan, J., Wang, Q., & Xue, W. (2022) · Theranostics · doi:10.7150/thno.73152 · Cited by 125 · see citing works
Malesci, A., Bianchi, P., Celesti, G., Basso, G., Marchesi, F., Grizzi, F., Di Caro, G., Cavalleri, T., Rimassa, L., Palmqvist, R., et al. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1342918 · Cited by 124 · see citing works
Chemotherapy and tumor microenvironment of pancreatic cancer
Liu, Q., Liao, Q., & Zhao, Y. (2017) · Cancer Cell International · doi:10.1186/s12935-017-0437-3 · Cited by 120 · see citing works
Nifuroxazide induces apoptosis and impairs pulmonary metastasis in breast cancer model
Yang, F., Hu, M., Lei, Q., Xia, Y., Zhu, Y., Song, X., Li, Y., Jie, H., Liu, C., Xiong, Y., et al. (2015) · Cell Death and Disease · doi:10.1038/cddis.2015.63 · Cited by 118 · see citing works
Tsao, M., Teuff, G. L., Shepherd, F. A., Landais, C., Hainaut, P. L., Filipits, M., Pirker, R., Chevalier, T. L., Graziano, S. L., Kratze, R., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx003 · Cited by 116 · see citing works
Role of Tumor-Associated Myeloid Cells in Breast Cancer
Cha, Y. J., & Koo, J. S. (2020) · Cells · doi:10.3390/cells9081785 · Cited by 114 · see citing works
Recent Advancements in Nanomedicine for ‘Cold’ Tumor Immunotherapy
Chen, Q., Sun, T., & Jiang, C. (2021) · Nano-Micro Letters · doi:10.1007/s40820-021-00622-6 · Cited by 113 · see citing works
Jinushi, M., & Komohara, Y. (2015) · Biochimica et Biophysica Acta · doi:10.1016/j.bbcan.2015.01.002 · Cited by 114 · see citing works
Moving on From Sipuleucel-T: New Dendritic Cell Vaccine Strategies for Prostate Cancer
Sutherland, S., Ju, X., Horvath, L. G., & Clark, G. J. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.641307 · Cited by 115 · see citing works
Kodumudi, K. N., Weber, A. M., Sarnaik, A. A., & Pilon‐Thomas, S. (2012) · The Journal of Immunology · doi:10.4049/jimmunol.1200274 · Cited by 111 · see citing works
Self-citationChronic inflammation and cancer: suppressing the suppressors
Baniyash, M., Sade-Feldman, M., & Kanterman, J. (2013) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-013-1468-9 · Cited by 111 · see citing works
Nagaraj, S., Nelson, A., Youn, J., Cheng, P., Quiceno, D. G., & Gabrilovich, D. I. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-2863 · Cited by 104 · see citing works
Koinis, F., Vetsika, E., Aggouraki, D., Skalidaki, E., Koutoulaki, A., Gkioulmpasani, M., Georgoulias, V., & Kotsakis, A. P. (2016) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2016.04.026 · Cited by 102 · see citing works
The innate and adaptive infiltrating immune systems as targets for breast cancer immunotherapy
Law, A. M. K., Lim, E., Ormandy, C. J., & Gallego‐Ortega, D. (2017) · Endocrine Related Cancer · doi:10.1530/erc-16-0404 · Cited by 102 · see citing works
Zhou, Y., Chen, C., Zhang, X., Fu, S., Xue, C., Ma, Y., Fang, W., Yang, Y., Hou, X., Huang, Y., et al. (2018) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-018-0477-9 · Cited by 102 · see citing works
Dendritic Cell Vaccination of Glioblastoma: Road to Success or Dead End
Datsi, A., & Sorg, R. V. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.770390 · Cited by 105 · see citing works
- Authors
- Kodumudi, K. N., Woan, K., Gilvary, D. L., Sahakian, E., Wei, S., & Djeu, J. Y.
- Affiliations
- Moffitt Cancer Center (US)
- Authors' Affiliation: Department of Immunology, H. Lee Moffitt Cancer Center, Tampa, Florida
- Corresponding author
- Djeu, Julie Y.
- Venue
- Clinical Cancer Research
- Published
- 2010-09-14
- Volume
- 16
- Issue
- 18
- Pages
- 4583-4594
- ISSN
- 1078-0432 (ISSN-L)
- 1557-3265
- PMC
- PMC3874864
- OpenAlex
- W2143994426
- Cited by
- 500
- References
- 42
- Citations by year
- 2026: 6 · 2025: 14 · 2024: 33 · 2023: 32 · 2022: 37 · 2021: 39 · 2020: 39 · 2019: 43 · 2018: 33 · 2017: 38 · 2016: 42 · 2015: 32 · 2014: 31 · 2013: 36 · 2012: 22
- FWCI
- 10.74
- Type
- journal article
- Language
- en
- Open access
- green
- europepmc.org
- Locations
- Clinical Cancer Research (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Cancer Institute (T32CA115308)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Immune cells in cancer
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Keywords
- docetaxel, myeloid-derived suppressor cells, tumor immunosuppression, CTL response, CD4+ T cell activation, CD206, CCR7, macrophage differentiation, STAT3 signaling, tumor-bearing mice
- MeSH terms
- Docetaxel, Animals, Antineoplastic Agents, Cell Differentiation, Cytotoxicity, Immunologic, Female, Immune Tolerance, Immunosuppressive Agents, Lymphocyte Activation, Mice, Inbred BALB C, Mice, Transgenic, Neoplasm Transplantation, Neoplasms, T-Lymphocytes, Myeloid Cells, Taxoids, Cell Line, Tumor, Mice, Immunomodulation
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
